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the DISC1 RNAi rescue, all not significantly different,
Figure 1e), suggesting that the effect of DISC1 is to
increase the fraction of mitochondria engaged in the
mobile phase rather than providing alternative path-
ways for more rapid movement.
Two non-synonymous single-nucleotide poly-
morphism variants of DISC1, Ser704Cys and
Leu607Phe, associate with schizophrenia, bipolar
disorder and major depression and have been linked
to differences in synaptic function and brain matura-
tion.1,8–10 We used shRNAi knockdown of DISC1
combined with coexpression of DISC1 variants resis-
tant to the shRNAi to replace endogenous DISC1 with
these variants and address whether the disease-
associated polymorphisms influence mitochondrial
trafficking. In neurons expressing shRNAi to knock
down DISC1, both the common variant (which
encodes Leu607/Ser704) and the Cys704 variant
could equally rescue mitochondrial trafficking, sug-
gesting no difference in these variants in regulating
mitochondrial transport. In contrast, compared with
the DISC1 common variant, the Phe607 DISC1 variant
was unable to correctly rescue mitochondrial move-
ment in DISC1 RNAi-expressing cells (28.78±2.7%
for DISC1 common variant rescue compared with
20.63±2.5% for Phe607 rescue, P=0.047; Figure 1f
and g). These results suggest that correct mitochon-
drial trafficking in neurons expressing the DISC1
Phe607 variant is significantly impaired.
Here, we report a novel role for DISC1 in regulating
the axonal transport of mitochondria and also show
that the disease-associated Leu607Phe polymorphism
disrupts this function. The ability of DISC1 to regulate
mitochondrial dynamics and associate with motor
proteins suggests that it is part of an essential motor
transport complex that directs mitochondrial traffick-
ing in neurons.1 Previous studies have revealed
diverse effects of DISC1 on synaptogenesis, neurite
outgrowth, neuronal migration and neurogenesis.1 We
propose that central to these effects is DISC1’s role in
the transport of mitochondria, an organelle whose
correct function and dynamic localization is essential
for neuronal development, communication and sig-
naling. Thus, the regulation of mitochondrial trans-
port and hence neuronal energy provision by DISC1
shown here represents a potentially exciting new
target for investigation of underlying mechanisms of
schizophrenia.
Conflict of interest
The authors declare no conflict of interest.
TA Atkin1, AF MacAskill1, NJ Brandon2
and JT Kittler1
1Department of Neuroscience, Physiology, and
Pharmacology, University College London, London,
UK and 2Pfizer Global Research and Development,
Neuroscience Research Unit, Groton, CT, USA
E-mail: j.kittler@ucl.ac.uk
References
1 Chubb JE, Bradshaw NJ, Soares DC, Porteous DJ, Millar JK. Mol
Psychiatry 2008; 13: 36–64.
2 MacAskill AF, Atkin TA, Kittler JT. Eur J Neurosci 2010; 32:
231–240.
3 Shao L, Martin MV, Watson SJ, Schatzberg A, Akil H, Myers RM
et al. Ann Med 2008; 40: 281–295.
4 Taya S, Shinoda T, Tsuboi D, Asaki J, Nagai K, Hikita T et al.
J Neurosci 2007; 27: 15–26.
5 James R, Adams RR, Christie S, Buchanan SR, Porteous DJ, Millar
JK. Mol Cell Neurosci 2004; 26: 112–122.
6 Macaskill AF, Rinholm JE, Twelvetrees AE, Arancibia-Carcamo IL,
Muir J, Fransson A et al. Neuron 2009; 61: 541–555.
7 Duan X, Chang JH, Ge S, Faulkner RL, Kim JY, Kitabatake Y et al.
Cell 2007; 130: 1146–1158.
8 Burdick KE, Kamiya A, Hodgkinson CA, Lencz T, DeRosse P,
Ishizuka K et al. Hum Mol Genet 2008; 17: 2462–2473.
9 Eastwood SL, Hodgkinson CA, Harrison PJ. Mol Psychiatry 2009;
14: 556–557.
10 Raznahan A, Lee Y, Long R, Greenstein D, Clasen L, Addington A
et al. Mol Psychiatry 13 July 2010; e-pub ahead of print.
Supplementary Information accompanies the paper on the Molecular
Psychiatry website (http://www.nature.com/mp)
Modulation of orbitofrontal
response to amphetamine
by a functional variant of
DAT1 and in vitro
confirmation
Molecular Psychiatry (2011) 16, 124–126; doi:10.1038/
mp.2009.6; published online 21 September 2010
Dopamine plays a key role in the reward pathways
within the brain. The plasma membrane dopamine
transporter (DAT1) is found exclusively in dopamine
neurones and regulates the reuptake of dopamine
from the synapse.1 A recently discovered polymorph-
ism, allele 3 of the variable number tandem repeat in
intron 8 (Int8 VNTR), has been linked with an
increased propensity to abuse cocaine.2 However, it
is not clear how this allele influences the cortical
substrate underlying reward processing. We describe
the effects of a functional genetic variant in DAT1 on
cortical activation during a functional magnetic
resonance imaging study of reward processing in
subjects treated with amphetamine.
Twenty subjects were randomized to receive either
placebo or amphetamine while undergoing functional
magnetic resonance imaging during a gambling task.
DNA was extracted from whole blood using a
modified phenol-chloroform procedure and genotyp-
ing conducted as described in Figure 1. Eleven
subjects possessed the at risk allele (allele 3 Int8
VNTR); of these, six received amphetamine and five
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received placebo. Of the nine subjects possessing the
lower risk allele, five received amphetamine and four
were given placebo.
All subjects were given d15 at the start of the
experiment, and required to risk d1 on each subse-
quent gambling trial. Each trial consisted of a
spinning roulette wheel, and the participants were
cued to select one of two colours. The subjects total
balance was updated with the win or losses.
Subjects underwent functional magnetic resonance
imaging scanning approximately 120min after the
administration of either amphetamine or placebo.
Imaging was performed with a 1.5T GE scanner (GE,
WI, USA) with a single run of 270 volumes (matrix
size 6464), with whole brain coverage, taking
18min. Each volume comprised 43 slices, collected
in an interleaved manner, with isometric 3mm
voxels and repetition time of 4 s (TE 40ms Flip
angle 90).
A factorial design (Genotype-x-Treatment) was used
to identify regions showing a significant interaction,
where task-related activity was modulated both by the
genetic status and stimulant exposure. This was
observed in only one region of the orbitofrontal cortex
(OFC) (P=0.018 corrected for cluster size) (Figure 1).
Subjects without the risk allele showed increased
activation of this region following placebo, but
reduced activation following amphetamine. However,
the converse relationship was observed in those with
the risk allele, with normal OFC activity only seen
following amphetamine administration.
One prominent contemporary hypothesis suggests
that reduced sensitivity to natural rewards may
lead predisposed individuals to take stimulant drugs
in an effort to gain this reward.3 The DAT is one of the
main targets for psychostimulant drugs and its
inhibition leads to significant elevation of dopamine
concentration1 in mesolimbic, mesocortical and ni-
grostriatal circuits. OFC and striatal areas are
connected enabling the signalling of values that guide
our behaviour, allowing inhibitory control of the
non-adaptative actions.4 Through the effect on this
mechanism, a functional polymorphism of DAT may
influence both the reinforcing effects of a drug within
the striatum, and have an upstream effect on the
representation of the saliency of the drug through
the OFC.
Animal and human studies support these results:
decreased DAT expression is related to hyperlocomo-
tion and worse adaptation to new environment in
mice,5 whereas in humans, it is associated with
chronic stimulant abuse and severity of positive
psychotic symptoms.6
Another indicator of dopamine system function,
striatal dopamine D2 receptor levels, has also been
shown to affect sensitivity to reward and orbitofrontal
metabolism, with low D2 receptors associated with a
blunted striatal and orbitofrontal reward response and
a predisposition to abuse drugs showing more
pleasurable effects and elevated OFC activity.7,8
These findings suggest that the altered orbitofrontal
function may contribute to behavioural disinhibition,
reflected in an increased compulsion to take stimu-
lant drugs, a core feature of addiction. The increased
OFC activity in cocaine abusers given methylpheni-
date, with decreases in non-addicts,9 and the atten-
tional bias in homozygous healthy subjects for the
risk allele10 support our results.
To confirm these effects, we examined the effect of
the Int8 VNTR 3 and 2 alleles on expression of a
reporter gene and its response to amphetamine. As
the location of the Int8 VNTR was within the gene,
away from the 50 or 30 regions, we used a modified
renilla vector with a unique intronic Asc1 site to
allow us to examine potentially interesting intronic
regulatory domains. The Int8 VNTR, when cloned in
this domain and transfected into the dopaminergic
SN4741 cell line, showed a reproducible and statis-
tically significant increase at baseline (Student’s
t=2.64, df = 27 and P<0.05) in reporter gene expres-
sion supported by the 2 allele of the Int8 VNTR versus
that supported by the 3 allele. We then tested the
response of the Int8 VNTR 2 and Int8 VNTR 3 alleles
to distinct challenges in the form of amphetamine,
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Figure 1 Orbitofrontal cortex (OFC) activity modulation by genotype and stimulant exposure. Placebo - - -E- - -,
amphetamine —’—; 23 low-risk allele, 33 high-risk allele. Right axis: OFC activity.
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potassium chloride (KCl) and KCl and Forskolin. The
relative effect of each stimuli, showed a significant
increased response of the vector containing the 3
allele compared with the 2 allele at every treatment
(P<0.01).
We thus have shown by the functional magnetic
resonance imaging that homozygotes for the 3 allele of
the Int8 VNTR in DAT1 show disruption of normal
reward related processes mediated by the OFC. This
is further confirmed by in vitro studies of vector
where the Int8 VNTR 3 allele shows a differential
effect on reporter gene expression in response to
amphetamine.
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A risk marker for alcohol
dependence on
chromosome 2q35 is
related to neuroticism in
the general population
Molecular Psychiatry (2011) 16, 126–128; doi:10.1038/
mp.2009.119; published online 30 March 2010
Alcohol dependence is a common disorder with a
high impact on health and socio-economy and has a
high genetic load.1 Here we show that the genetic
marker rs7590720, for which we recently showed
significant association (P<9.72 109) with alcohol
dependence in a genome-wide association study
(GWAS)2, is also related to human personality in the
general population.
Alcohol dependence is a phenotypically hetero-
geneous disorder and has a variety of underlying
causes. Several, if not many, genes with modest effect
have an impact on the disorder.3 It is assumed that
some of these genes are common vulnerability genes
that are also found at a high frequency in the general
population and should have a measurable impact on,
for example, continuous and quantitative personality
traits. In line with this, different personality traits
have been found to be implicated in alcohol depen-
dence. For example, a more introverted personality
type with high neuroticism in combination with
depressive traits, as well as a more extraverted
personality type with antisocial behaviour, high
impulsivity and low neuroticism, might lead to
alcohol dependence.4–6
A recently reported GWAS on alcohol dependence
was performed in male subjects with a severe
phenotype and an early age at onset. The identified
marker rs7590720 is located on chromosome 2q35, a
region that has already been implicated in linkage
studies for alcohol phenotypes.2 We now sought to
test the impact of the top variant rs7590720, for
association with personality traits in a population-
based approach.
Consecutively recruited, Caucasian subjects
(n=1592) from the Study of Health in Pomerania
(SHIP)7,8 which is carried out in northeastern Ger-
many, were eligible for analyses. Personality traits
were assessed using the NEO-FFI-30,9 which is a 30-
item short version of the NEO-Five-Factor Inventory
by Costa and McCrae.10 This personality assessment
measures the following five personality dimensions:
Neuroticism, Extraversion, Openness to experience,
Agreeableness and Conscientiousness. The SCID-1
(structured clinical interview for Diagnostic and
Statistical Manual, Fourth Edition (DSM-IV)) diag-
nostic interview assessment for alcohol dependence
was available for 1576 subjects. The SHIP sample
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